Kainos Laboratories

Kainos Laboratories Gross Margin

Delisted

The Gross Margin of Kainos Laboratories (4556.T) as of Nov 17, 2026 is 50.41 %. In the previous year, Gross Margin was 50.46 % — a change of -0.11% (lower).

Gross Margin

50.41 %

YoY

-0.11%

Last updated:

Gross Margin of Kainos Laboratories is 2025 50.41 % . Gross Margin of Kainos Laboratories was 2024 50.46 % . It decreases by -0.11% lower compared to the previous year.

Kainos Laboratories's gross margin stands at 50.4%, down from 54.3% several years earlier.

The Kainos Laboratories Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
45.88 JPY
Jan 1, 2019
48.56 JPY
Jan 1, 2020
51.62 JPY
Jan 1, 2021
54.28 JPY
Jan 1, 2022
52.17 JPY
Jan 1, 2023
51.05 JPY
Jan 1, 2024
50.46 JPY
Jan 1, 2025
50.41 JPY
The Kainos Laboratories Gross Margin history
YEARGross MarginYoY
50.41 %-0.11%
50.46 %-1.15%
51.05 %-2.14%
52.17 %-3.88%
54.28 %+5.15%
51.62 %+6.30%
48.56 %+5.83%
45.88 %-0.23%
45.99 %+16.39%
39.51 %+5.52%
37.44 %+13.08%
33.11 %+10,187.30%
0.32 %-3.14%
0.33 %-3.87%
0.35 %-4.62%
0.36 %+2.39%
0.35 %+2.54%
0.35 %-1.07%
0.35 %-6.41%
0.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

Gross Margin of Kainos Laboratories is 50.41 % in 2025.

Gross Margin of Kainos Laboratories changed from 50.46 % to 50.41 %, representing a -0.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Kainos Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Kainos Laboratories

All Key Metrics — Kainos Laboratories